Ovarian tumors: a case series from a tertiary care center
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253909Keywords:
Ovarian tumors, Case series, High-grade serous carcinoma, Mucinous cystadenocarcinoma, DysgerminomaAbstract
Ovarian cancer is the third most common malignancy among women in India and accounts for approximately 6% of cancer-related deaths, with late-stage presentation being frequent due to vague and nonspecific symptoms. This case series describes twelve patients with ovarian neoplasms diagnosed over six months at a tertiary care center, highlighting the clinical diversity and age-related distribution of these tumors. Most cases were observed in postmenopausal women above 50 years of age, with histopathological types ranging from high-grade serous carcinoma and mucinous carcinoma to mucinous cystadenoma, granulosa cell tumor, dysgerminoma, and metastatic malignant melanoma. Clinical manifestations included abdominal pain, distension, ascites, respiratory difficulty, and in one case, incidental detection during infertility evaluation. Risk factors such as nulliparity, delayed childbearing, and family history were noted. Management strategies varied from surgical excision for benign lesions to cytoreductive surgery with adjuvant chemotherapy for malignant cases. This study underscores the heterogeneity of ovarian tumors and the critical importance of early recognition, accurate histopathological classification, and individualized treatment planning. Despite advances in surgical and chemotherapeutic modalities, prognosis in advanced disease remains poor, emphasizing the need for improved screening strategies, molecular research, and targeted therapies to enhance survival and quality of life.
Metrics
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-7. DOI: https://doi.org/10.1002/cncr.22371
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296(2):185-92. DOI: https://doi.org/10.1001/jama.296.2.185
Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237-49. DOI: https://doi.org/10.1007/s00428-012-1203-5
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32. DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0084
Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013;122(2):225-32. DOI: https://doi.org/10.1097/AOG.0b013e31829ce7ec
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: https://doi.org/10.3322/caac.21763
Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer—the Indian scenario. Asian Pac J Cancer Prev. 2009;10(6):1025-30.
Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459-67. DOI: https://doi.org/10.1093/jnci/91.17.1459
Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: A qualitative and quantitative study. Br J Obstet Gynecol. 2008;115(8):1008-14. DOI: https://doi.org/10.1111/j.1471-0528.2008.01772.x
Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733-47. DOI: https://doi.org/10.1016/j.ajpath.2015.11.011
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. J Natl Compr Canc Netw. 2021;19(2):191-226. DOI: https://doi.org/10.6004/jnccn.2021.0007
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. DOI: https://doi.org/10.1056/NEJMoa0908806
Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:20-6. DOI: https://doi.org/10.1093/annonc/mds223
Ueland FR. A perspective on ovarian cancer biomarkers: past, present and future. Int J Gynecol Cancer. 2011;21(5):800-6.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416-28. DOI: https://doi.org/10.1056/NEJMoa1911361